CRISPR cell therapy trial for tough lupus cases withdrawn before starting
NCT ID NCT06752876
Summary
This early-stage study aimed to test the safety and initial effects of a single infusion of CB-010, a new type of cell therapy modified with CRISPR gene-editing, in adults with severe lupus that hasn't responded to standard treatments. The trial was designed to last about two years but was withdrawn by the sponsor before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.